ArticleClinical rheumatology2025
The global burden and epidemiological trends of gout, particularly cases attributable to high Body Mass Index (BMI) in adolescents and young adults (aged 15-39 years): a secondary analysis from global burden of disease study 2021.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Global burden and trends of non-communicable diseases among children and adolescents from 1990 to 2021: an age-period-cohort and frontier analysis with projections to 2035.Frontiers in public health · 2026Article
- Global burden of gout attributable to high BMI (1990-2021) and causal link with obesity: a GBD and Mendelian randomization study.Therapeutic advances in endocrinology and metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to analyze the burden and epidemiological trends of early-onset gout (EOG) and its association with high body mass index (BMI) in individuals aged 15 to 39 globally from 1990 to 2021.
methodsUsing the Global Burden of Disease (GBD) 2021 data, global incidence, prevalence, disability-adjusted life years (DALYs), and DALYs attributable to high BMI were analyzed. We examined EOG burden across global, regional, and national levels, along with trends, decomposition, health inequality, and correlations with socio-demographic index (SDI).
resultsIn 2021, EOG accounted for 1,296,983 incident cases globally, with 5,077,197 prevalent cases and 170,599 DALYs, of which 54,909 were attributed to high BMI. The age-standardized incidence rate (ASIR) rose from 36.52 per 100,000 in 1990 to 43.60 per 100,000 in 2021. Significant regional variations were observed, with high-income North America having the highest incidence (115.02 per 100,000). EOG burden was higher in males. Additionally, the percentage of DALYs attributable to high BMI continues to rise. EOG burden growth was mainly due to population growth, while DALYs attributable to high BMI rose due to epidemiological shifts. Absolute inequality in EOG burden grew, but relative inequality remained moderate. DALYs attributable to high BMI were concentrated in regions with higher SDI.
conclusionsThe global burden of EOG has increased from 1990 to 2021, with high BMI playing a significant role. Strengthened prevention and management of gout and high BMI in adolescents and young adults are necessary. Key Points • The study investigates the spatiotemporal trends of incidence, prevalence, and DALYs of early-onset gout (aged 15-39 years) globally over the past 30 years, as well as the impact of high BMI on its DALYs. • The findings reveal a significant increase in the global burden of early-onset gout from 1990 to 2021, with both the number and proportion of DALYs attributable to high BMI showing marked increases across different sexes, age groups, and SDI levels. • The burden of early-onset gout is distributed unevenly across regions and countries, with a clear correlation to SDI levels, and the burden is concentrated in countries with higher SDI.
Indexed as
Identifiers
40533689What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.